Continuous use of ART was the most important determinant of the virological outcome regardless of mode of transmission. We found that the reduction over time in the proportion of patients with low CD4 cell counts was higher in the patients treated for ≥6 months, and similar in the other strata. In fact, upon initiation of ART, immunological reconstitution needs more time to be achieved compared with viral suppression. It is interesting to note that IDUs seemed to benefit less over time in terms of Ku-0059436 in vivo CD4
cell count despite a similar benefit in terms of VL. Before drawing final conclusions, some limitations of this analysis should be discussed. First, Icona typically includes HIV-infected patients who are ART-naïve at enrolment and therefore it depicts the clinical course
of healthier patients than those seen in an average infectious disease clinic in Italy. Therefore, our overall estimate of the effect of ART may be somewhat optimistic compared with that occurring in an unselected population. Secondly, the trends over time may have been affected by loss to follow-up in the cohort. Nevertheless, when we repeated the analysis after excluding patients who had not returned for a visit for some time, we found similar results for the VL outcome and an even stronger effect of calendar year for the CD4 cell count outcome. In conclusion, this analysis confirms that the use of ART in Italian clinics over the last decade has led to a significant decrease in the percentage SB203580 solubility dmso of patients with an adverse viro-immunological prognosis. The decline in the prevalence of a poor virological prognosis was particularly marked when the analysis was restricted to patients who had been treated for ≥6 months. This is reassuring in the light of the fact that ART needs to be taken for life. Of note, we found that IDUs seemed to have experienced virological improvements over time comparable to those observed in patients infected via heterosexual contact, although they seemed to have benefited
less from ART in terms of CD4 cell count response than other transmission groups. M. Moroni (Chair), A. Antinori, G. Carosi, R. Cauda, A. d’Arminio Monforte, G. Di Perri, M. Galli, F. Ghinelli, R. Iardino, G. Ippolito, A. Lazzarin, F. Mazzotta, R. Panebianco, Miconazole G. Pastore and C. F. Perno. A. Ammassari, A. Antinori, C. Arici, C. Balotta, P. Bonfanti, M. R. Capobianchi, A. Castagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, A. d’Arminio Monforte, A. De Luca, C. Gervasoni, E. Girardi, S. Lo Caputo, F. Maggiolo, R. Murri, C. Mussini, M. Puoti and C. Torti. A. Cozzi-Lepri, I. Fanti, T. Formenti and M. C. F. Prosperi. M. Montroni, A. Giacometti, A. Costantini and A. Riva (Ancona); U. Tirelli and F. Martellotta (Aviano-PN); G. Pastore, N. Ladisa and A. Pierri (Bari); F. Suter and F. Maggiolo (Bergamo); M. Borderi, G. Verucchi and B. Piergentili (Bologna); G. Carosi, G. Cristini, C. Torti, C. Minardi and D.